Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Suhag Patel

Physician Assistant Williamsport, PA Physician Assistant

NPI 1891305579 CMS profile 11094096

740 High St Ste 3002, Suite 3002, Williamsport, PA 17701

Open in the dashboard

General payments

$19,235

141 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Suhag Patel of Williamsport, PA is reported in the CMS Open Payments database as having received $19,235 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,397 28
2024 General $7,883 56
2023 General $4,239 37
2022 General $1,143 13
2021 General $574 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suhag Patel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Suhag Patel were reported at $5,397. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Suhag Patel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $574 $132 $37–$438 $132
2022 $1,143 $155 $48–$522 $149
2023 $4,239 $167 $52–$557 $160
2024 $7,883 $178 $55–$600 $164
2025 $5,397 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $13,016 42 payments
  2. LivaNova USA, Inc. $1,069 15 payments
  3. EMD Serono, Inc. $792 13 payments
  4. Nevro Corp. $720 12 payments
  5. Novartis Pharmaceuticals Corporation $677 12 payments
  6. Pfizer Inc. $445 6 payments
  7. Novo Nordisk Inc $418 6 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $311 3 payments
  9. Lundbeck LLC $281 6 payments
  10. Celgene Corporation $268 12 payments
  11. Other $1,236 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,700 13 payments
  2. Food and Beverage $7,103 118 payments
  3. Travel and Lodging $407 8 payments
  4. Education $25 2 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $9,610 31 payments
  2. UBRELVY $8,245 23 payments
  3. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $807 12 payments
  4. Senza $583 10 payments
  5. NURTEC ODT Pain $445 6 payments
  6. KESIMPTA $434 9 payments
  7. ZEPOSIA $384 13 payments
  8. NURTEC ODT Primary Care $350 4 payments
  9. RYBELSUS $278 4 payments
  10. ZAVZPRET $276 3 payments
  11. Other $2,517 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

4,396

Median for Physician Assistant: 241

Drug cost

$1,452,444

Median for Physician Assistant: $4,110

Branded share of claims

36.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 35 $330,110
Nurtec Odt Rimegepant Sulfate Brand 213 $288,233
Emgality Pen Galcanezumab-Gnlm Brand 213 $185,395
Aimovig Autoinjector Erenumab-Aooe Brand 117 $90,725
Glatiramer Acetate Generic 14 $80,447
Ubrelvy Ubrogepant Brand 57 $55,367
Glatopa Glatiramer Acetate Brand 21 $52,150
Lamictal Lamotrigine Brand 24 $41,105
Epidiolex Cannabidiol (Cbd) Brand 13 $39,728
Ajovy Autoinjector Fremanezumab-Vfrm Brand 42 $33,844

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $4,075
$4,075 28 —
UBRELVY
  • AbbVie, Inc. $1,718
$1,718 57 —
NURTEC ODT
  • PFIZER INC. $200
$200 213 —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $177
$177 35 —
ZEPOSIA
  • Celgene Corporation $161
$161 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record